Malaysia
Search
Sign In
Change Password
Points
Sign Out
Pharmacy
Top Medical News
Preconception treatment with levothyroxine fails to bring significantly better cognitive outcomes in children up to age 2 years compared with treatment initiated at 8–14 weeks of gestation, a study has found.
IV acetaminophen does not reduce the duration of postoperative hypoxaemia over 48 hours compared with placebo among patients who have undergone abdominal surgery, the FACTOR trial has shown.
There is not enough irrefutable evidence that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists have positive effects on cognition in patients with type 2 diabetes mellitus (T2DM), according to a study.
New drug applications approved by US FDA as of 16 - 30 September 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
For paediatric pneumonia with fast breathing (tachypnoea), the WHO*-recommended treatment with amoxicillin is still the preferred regimen, suggests the RETAPP** study.
Implementation of an advanced pharmacy practice model has “maximized opportunities” for pharmacists to provide direct patient care, practice “at the top of their license,” and promote safe and effective use of medications, according to a retrospective descriptive study.
Patients with atrial fibrillation (AF) enrolled in the prospective Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF) have been prescribed the recommended direct oral anticoagulant (DOAC) doses according to country-specific guidelines. However, use of nonrecommended doses persists and is associated with a higher risk of death, mostly of cardiovascular nature, reveals a study.
Special Reports
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Single-inhaler triple-therapy (SITT) comprising FF/UMEC/VI* is preferred over dual therapies (DT) or multiple-inhaler (MI) TT for managing COPD**, according to data presented at ERS 2020.
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
GALVUS MET – Vidagliptin, metformin HCl 50 mg/500 mg, 50 mg/850 mg and 50 mg/1,000 mg FC tab
COSYREL – Bisoprolol fumarate, perindopril arginine 5 mg/5 mg, 5 mg/10 mg and 10 mg/10 mg FC tab
Conference Reports
The use of aspirin alone following TAVI* significantly reduced bleeding vs aspirin plus clopidogrel in the POPular TAVI study. This benefit came without increasing thromboembolic events, effectively positioning aspirin as the better antithrombotic strategy after TAVI.
A 4-week course of amoxicillin-clavulanate in children with protracted bacterial bronchitis (PBB) does not improve cough resolution rates compared with a 2-week course, according to a study from Australia. However, the longer course may significantly extend time to first cough exacerbation.
With much remains controversial regarding the possible transmission route of SARS-CoV-2 virus, a study reveals yet another surprise worthy of caution in the hospital setting.
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Patients with moderate-to-severe asthma had significant reductions in annualized severe asthma exacerbation rate with the monoclonal antibody dupilumab, regardless of lung function, according to a post hoc analysis of LIBERTY ASTHMA QUEST* presented at ERS 2020.
Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.
Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
Multimedia
